Interpretation to the Update Key Points of International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023
10.3760/cma.j.cn101441-20231007-00148
- VernacularTitle:《2023多囊卵巢综合征评估和管理国际循证指南》更新要点解读
- Author:
Chanjuan ZENG
1
;
Ying ZOU
1
Author Information
1. 湖南省妇幼保健院妇科内分泌中心，长沙 410028
- Publication Type:Journal Article
- Keywords:
Polycystic ovary syndrome;
Guideline;
Anti-Müllerian hormone;
Interpretation;
Update
- From:
Chinese Journal of Reproduction and Contraception
2023;43(11):1114-1119
- CountryChina
- Language:Chinese
-
Abstract:
Polycystic ovary syndrome (PCOS) is a common endocrinopathy affecting reproductive aged women, leading to infertility and menstrual disorders, and increasing the risk of cardiometabolic diseases, reproductive tumors, and emotional and psychological disorders in later life. In order to aid healthcare professionals and consumers in decisions about appropriate and effective care, and to provide a better approach to the "full life cycle management of PCOS", the European Society of Human Reproduction and Embryology and American Society for Reproductive Medicine published international evidence-based guidelines in 2018, and the guidelines were updated in August 2023 by integrating new evidence-based evidence, in collaboration with the Endocrine Society and European Society of Endocrinology. This article introduces and explains the key points of the new guideline update.
